Hubbry Logo
Express ScriptsExpress ScriptsMain
Open search
Express Scripts
Community hub
Express Scripts
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Express Scripts
Express Scripts
Express Scripts
View on Wikipedia
from Wikipedia

Express Scripts Holding Company is a pharmacy benefit management (PBM) organization. In 2017 it was the 22nd-largest company in the United States by total revenue as well as the largest pharmacy benefit management (PBM) organization in the United States.[2] Express Scripts had 2016 revenues of $100.752 billion.[2] Since December 20, 2018, the company has been a direct subsidiary of Bloomfield, Connecticut-based Cigna.

Key Information

The term "Scripts" in the company title refers to the widely used clipped version of the term prescriptions.

Headquartered in Greater St. Louis within unincorporated North St. Louis County, Missouri, Express Scripts provides integrated pharmacy benefit management services including network-pharmacy claims processing; home delivery pharmacy services; specialty pharmacy benefit management, through its subsidiary Accredo; benefit-design consultation; drug-utilization review; formulary management; and medical and drug data analysis services to manage drug plans for health plans, self-insured employers and government agencies (both as administrator of employee benefits and public assistance programs). One of its largest clients is the United States Department of Defense's Tricare program.[4]

Express Scripts also offers pharmacy benefit management services for workers' compensation insurance programs. The program is accredited by URAC, the nation's largest accrediting body for pharmacy benefit management companies.

The company processes pharmaceutical claims for members through a network of retail pharmacies. Its own automated pharmacies dispense medications for chronic long-term diseases, such as diabetes or heart disease, directly to members by home delivery.[5]: 4 

On March 7, 2018, it was announced that Cigna would buy Express Scripts in a $67 billion deal.[6][7] The deal closed on December 20, 2018 at $54 billion, allowing Cigna to start offering new Express Scripts products to its corporate health insurance customers in 2019.[8]

History

[edit]

Founding

[edit]

Express Scripts began in 1986 in St. Louis County, Missouri as a result of a joint venture between a retail chain of more than 79 pharmacies (Medicare Glaser Inc.) and Sanus Corp. Health Systems.

Sanus traces its history to Bradford Systems and Administrative Services which was founded in Boston in 1968. Bradford had a contract for computer processing of Medicare and Medicaid payments. It was acquired in 1981 by McDonnell Douglas through its McDonnell Automation Company (McAuto) subsidiary for $11.5 million.[9]

In 1983, two of McDonnell Douglas' former principals Joseph T. Lynaugh (a former director of NYC Health + Hospitals in New York City), the McAuto's project manager of the Bradford takeover,[10] and Howard L. Waltman, a long time Bradford's employee,[11] formed the Sanus Corporation with substantial investments and ownership from McDonnell Douglas, including a McDonnell Douglas whole ownership of the St. Louis office. General American Life Insurance Company invested in Sanus's future, the largest part of the funding based in New York. Sanus was a health maintenance organization and it merged with the General America Life Insurance preferred provider organization.[12] Sanus rapidly grew and by 1986 it had 200,000 clients and $100 million in revenue, operating in the St. Louis, Dallas, Fort Worth, Houston, and Washington, D.C. markets. It created a subsidiary called GenCare to fill prescriptions.

In late 1986, Sanus announced a deal with St. Louis based pharmacy Medicare-Glaser for fulfilling prescriptions. The deal was a 50-50 split ownership between Sanus and Medicare-Glaser, with the new name of Express Scripts (scripts being medical industry jargon for prescriptions). Initial plans called for Missouri and Illinois clients to get their prescriptions at the Medicare-Glaser brick and mortar pharmacies while those in other cities could get their prescriptions via mail order—an innovation at the time.[13] The initial report of the creation said that Charles H. Ridings, formerly in charge of McDonnell Douglas mergers and acquisitions, was named the first chief executive, although he was quickly replaced by Waltman.[14]

Sanus remained the dominant early insurance customer but Express Scripts began marketing to other providers. With increased investment by New York Life, Sansus change its name to NYL Cares and in 1998 was sold to Aetna for $1.05 billion.[15]

Glaser Drug Company sold its Express Scripts partnership interest back to Sanus before it was acquired by chain SupeRx in 1989 for $18.2 million. SupeRX declared bankruptcy and all stores closed in 1991 after Walgreens acquired the pharmacy records. SupeRX's loan to buy Glaser Drug Co. had been financed by Lincoln Savings and Loan Association. Morris Glaser had founded the company on October 1, 1924. In 1959, Glaser opened discount pharmacies, which would be called Medicare Pharmacy. The discount pharmacies were designed to resemble a doctor waiting room and were only about 800 to 1,000 square feet which focused just on the prescriptions. The two companies although sharing the same name operated separately, peaking at 100 stores.[16]

General America, which had been a private St. Louis-based insurance since 1933, was acquired by MetLife for $1.2 billion in 1999. General America had run into financial problems and had said it could not pay back $6.8 billion in short term bonds to investors.[17][18]

1989-1999

[edit]

Express Scripts was purchased by New York Life Insurance Company in 1989 and became a publicly traded company in 1992.[19] In 1993, Express Scripts signed on both FHP International and Maxicare Health Care and corporate clients Lockheed, Service Merchandise, and Ingersoll-Rand.[19][20] In 1994, the company expanded its services by adding workers’ compensation prescription services and reinsurance.[20] In 1994, the company announced a two-for-one stock split, and in 1996 established Express Scripts Canada.[19] The same year, the company began the annual Drug Trend Report and launched the Outcomes Symposium Conference.[19]

In April 1998, Express Scripts acquired ValueRx, the PBM business of Columbia/HCA Healthcare Corp.[20] The following year, in April 1999, the company purchased Diversified Pharmaceutical Services from SmithKline Beecham Corp for $700 million.[20] That same year, the company purchased stock in PlanetRx.com.[20] This partnership offered members options for purchasing prescriptions and over-the-counter health products online.[20]

2000-2009

[edit]

In 2000, the company had to write off its $165 million relationship with PlanetRx.com when the startup experienced financial difficulties.[20] In 2001, Express Scripts partnered with Merck-Medco and Advance PSC to form RxHub LLC.[20]

In 2002, Express Scripts, Inc. (ESI) acquired National Prescription Administrators, Inc. (NPA).[21]

In 2003, Express Scripts won a contract to manage the Tricare pharmacy home delivery program for the US Department of Defense; in 2008, Express Scripts won a further contract to manage all Tricare prescription services.[22]

In late December 2006, Express Scripts made a proposal to purchase Caremark. Express Scripts lost the race to acquire Caremark to CVS Corporation, which became CVS/Caremark Corporation on March 22, 2007.[23]

In October 2007, Express Scripts acquired ConnectYourCare, and now handles FSA, HRA and HSA accounts for companies such as Suntrust, Zions Bancorporation and Allegis.[24] However, Express Scripts divested ConnectYourCare in August 2012.[24][25]

On April 13, 2009, it was announced that Indianapolis-based WellPoint (now Anthem) had agreed to sell its NextRx subsidiaries for $4.675 billion to Express Scripts.[26] Express Scripts closed the transaction in December 2009.[27]

2010-present

[edit]

In April 2012, Express Scripts completed a $29.1 billion acquisition of Medco Health Solutions.[28] The Federal Trade Commission gave formal approval on April 2, 2012 after an anti-trust investigation.[28] The acquisition positioned Express Scripts Holding Co. as the largest pharmacy benefit manager, filling 1.4 billion annual prescriptions.[28]

In 2017, Express Scripts launched Inside Rx, a partially owned subsidiary that provides discounts on medications for the uninsured and underinsured.[29] In July 2017, Express Scripts purchased myMatrixx, a workers' compensation pharmacy benefits company based in Tampa, for $250 million.[30]

In October 2017, Express Scripts lost its biggest client, Anthem, which said it would not renew the PBM contract in 2019 and would instead use CVS Health. Anthem alleged in court filings that Express had overcharged it by $3 billion.[31] Anthem said that it would launch its own competing PBM service, IngenioRx. The battle between the two companies in 2017 caused Express Scripts stock to drop by nearly a third.[32] Express Scripts announced its acquisition of eviCore in October 2017. The $3.6 billion deal closed that December.[33][34][35] In November 2017, Express Scripts announced it was divesting United BioSource Corp. (UBC), its pharmaceutical support business. UBC was sold to Avista Capital Partners.[36][37][38]

In March 2018, Cigna, which earlier was blocked by courts from being acquired by Anthem, announced a $67 billion deal to acquire Express Scripts. The Express Scripts acquisition would be the last major deal involving the country's largest PBMs. In 2017, CVS Health announced a merger with Aetna, completing in November 2018.[39] The takeover of PBMs have drawn regulator resistance because of fears they foster an anti-competitive environment. Insurance companies have charged that the PBM model has contributed to high drug prices because PBMs take a commission on each transaction.[40][41]

In December 2018, it was reported that Walmart and Express Scripts extended its network agreement to give Express Scripts' clients access to Walmart's prescription services.[42]

In December 2019, Express Scripts entered into a three-year partnership with Prime Therapeutics.[43]

In late 2020, Express Scripts and several subsidiaries were rebranded and reorganized into a distinct health services organization, Evernorth.[44] Evernorth CEO Tim Wentworth retired at the end of 2021 and Cigna veteran executive Eric Palmer became Evernorth CEO starting in 2022.[45]

Finances

[edit]

For the fiscal year 2017, Express Scripts reported earnings of US$4.517 billion, with an annual revenue of US$100.065 billion, a decline of 0.2% over the previous fiscal cycle. Express Scripts shares traded at over $64 per share, and its market capitalization was valued at over US$53.6 billion in October 2018.[46]

Year Revenue
in mil. USD$ 		Net income
in mil. USD$ 		Total Assets
in mil. USD$ 		Price per Share
in USD$ 		Employees
2005 16,188 400 5,494 13.65
2006 21,563 474 5,108 19.49
2007 21,824 568 5,256 25.40
2008 21,941 776 5,509 32.77
2009 24,722 828 11,931 33.61
2010 44,973 1,181 10,558 48.71
2011 46,128 1,276 15,607 50.92
2012 93,714 1,313 58,111 55.87
2013 104,099 1,845 53,548 61.67 29,975
2014 100,887 2,008 53,748 73.66 29,500
2015 101,752 2,476 53,243 86.01 25,900
2016 100,288 3,404 51,745 72.98 25,600
2017 100,065 4,517 54,256 64.41 26,600

World headquarters

[edit]
1 of 6 Express Scripts Headquarters buildings in April 2013

Express Scripts is headquartered within Greater St. Louis in North St. Louis County, Missouri.

In 2007, the company became the first and only Fortune 500 company to open a headquarters on a college campus when it opened its headquarters at 1 Express Way on the north edge of the University of Missouri–St. Louis north of University Place Drive and south of Interstate 70. A second headquarters building adjoining the original one opened in 2008. Three additional structures have been added to the NorthPark development on the north side of I-70 including an Office and Data Center, Tech and Innovation Center, and Operations Center. The area north of I-70 is separate from the university.[47] In 2018 the majority of the 5,000 St. Louis Express Scripts employees work in the complex.[47]

Aerial view of 1 Express Way in St. Louis County, MO

George Paz, CEO of Express Scripts at the time of the move, was an UMSL graduate.[48] Express Scripts, which rather owns both its headquarters and nearby office buildings, received substantial tax breaks.[49] Since the move the company has been an active partner with the university including contributing money to renovate the computer sciences building (Express Scripts Hall),[50] raising funds for building projects, sponsoring a pre-collegiate bridge program for high school students and sponsoring a small business incubator.

Express Scripts throughout its entire history has been in St. Louis County, Missouri rather than the City of St. Louis. It was originally headquartered in Maryland Heights, Missouri, and its current headquarters is about 4 miles west of the St. Louis city limits and its two building headquarters campus is actually spread across three jurisdictions. The entrance to the main building is located in Cool Valley, Missouri.[51] The southeast portion of the campus is in Bellerive, Missouri[52] and the southwest corner of the two-building complex is in unincorporated St. Louis County.[53] The three buildings north of I-70 are in Berkeley, Missouri.[54]

Chief executives

[edit]

Drug Trend Report

[edit]

Published annually since 1993, the Express Scripts Drug Trend Report provides detailed analysis of prescription drug costs and utilization.[20][57] Now a web-based version, the Drug Trend Report is developed and published by the Express Scripts Research & New Solutions Lab with contributors from researchers, clinicians and others.[58] This type of research is designed to understand consumer behavior relative to healthcare benefits.[59][60]

Health decision science

[edit]

Upon the merger of Express Scripts and Medco Health Solutions, the company came up with its own approach to understand its members health concerns, which it has dubbed Health Decision Science. This involves looking at three scientific disciplines: behavioral science or “consumerology”, clinical specialization, and actionable data.[61][62] Because of its position between pharmacies and health care plans, Express Scripts sees 1.4 billion prescriptions a year, and it uses this information as part of its research data to create better options for clients and patients.[63][64][65]

Controversy

[edit]

Fraud allegations

[edit]

On August 4, 2004, New York State Attorney General Eliot Spitzer filed a lawsuit against Express Scripts alleging that the company had kept tens of millions of dollars in drug rebates owed to the state. The suit was filed in the New York Supreme Court in Albany County.[66] The lawsuit further claimed that Express Scripts had overstated the cost benefits of switching to certain preferred medications. In 2008 the company settled the lawsuit, agreeing to pay $9.3 million to Pennsylvania and 28 other states to resolve claims of deceptive business practices. As part of the settlement, the company also agreed to change its business practices and pay up to $200,000 in reimbursement to patients.[67]

Information breach

[edit]

In October 2008, the St. Louis headquarters received an anonymous letter that contained sensitive information about 75 members.[68] The extortionist stated that they would release more of similar records if the company failed to pay an unspecified amount of money. A consumer class action lawsuit against Express Scripts was brought on by John Amburgy, a Missouri man, who accused the company of negligence in protecting customer records. The case was dismissed when Amburgy failed to show how he was directly affected by the breach.[69]

Rockford lawsuit

[edit]

The city of Rockford, Illinois is now[when?] suing Mallinckrodt Pharmaceuticals and Express Scripts for their failure to reduce the prescription drug Acthar's price. The suit alleges that Express Scripts had a contract to be the exclusive distributor of Acthar, and therefore benefited from its higher price. The company said in an email to 60 Minutes that there was no conflict of interest.[70]

Reimbursements

[edit]

Express Scripts is known to reimburse pharmacies below cost for medications and push patients to only use their mail order service. They then will spread price the medication and charge the plan sponsor a much higher price for the medication than they will reimburse pharmacies for.[71]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Express Scripts

View on Grokipedia
from Grokipedia

Express Scripts is a pharmacy benefit manager (PBM) that administers benefits for health plans, employers, unions, and government programs in the United States, processing claims, negotiating drug prices with manufacturers, and operating mail-order and specialty pharmacies to enhance medication access and affordability. Founded in 1986 and originally headquartered at 1 Express Way in , , the company grew through acquisitions into one of the largest PBMs, handling tens of millions of members before its $67 billion acquisition by Cigna Corporation in December 2018, after which it integrated into Cigna's Evernorth division while retaining its brand for PBM services. Express Scripts' core operations include developing formularies to guide drug coverage, leveraging its network for retail fills, and providing for maintenance medications, which collectively aim to reduce overall pharmaceutical spending through volume-based rebates and generic promotion—saving clients an estimated $38 billion annually in self-reported figures prior to the merger. The firm has achieved scale with pre-acquisition revenues exceeding $100 billion and a of about 26,600 employees, enabling it to influence drug utilization patterns and negotiate directly with pharmaceutical suppliers. Notable for its data-driven approaches to adherence and cost containment, Express Scripts has nonetheless encountered significant controversies over PBM industry practices, including opaque rebate retention, spread pricing between reimbursements and payments, and potential incentives that prioritize high-cost drugs, prompting federal investigations and legislative scrutiny into whether such mechanisms truly lower net costs or exacerbate affordability issues for patients. These debates highlight causal tensions in the , where PBMs' intermediary role facilitates discounts from manufacturers but has been empirically linked in some analyses to sustained inflation and margin squeezes.

History

Founding and Early Development (1986–1988)

Express Scripts was established in 1986 in St. Louis, Missouri, as a joint venture between Medicare-Glaser Inc., a retail pharmacy chain operating more than 79 locations, and Sanus Corp. Health Systems, a health maintenance organization seeking to control prescription costs for its members. The venture leveraged Medicare-Glaser's pharmacy expertise and Sanus's insured base to pioneer mail-order fulfillment, addressing rising healthcare expenses amid the expansion of managed care in the 1980s. This model emphasized centralized processing to streamline claims, reduce administrative burdens, and enable bulk purchasing for efficiency. Initial operations commenced with manual prescription filling and rudimentary , such as basic conveyor systems for . The company's first mail-order deliveries occurred on February 3, 1987, consisting of 11 prescriptions shipped to Sanus beneficiaries, establishing Express Scripts as an early innovator in services. Sanus remained the primary customer, accounting for the bulk of early volume, while the firm handled claims adjudication and benefit coordination to optimize drug utilization and costs. By 1988, Express Scripts had secured investment from , which provided funding to scale and expand beyond its foundational client. This capital infusion supported initial marketing efforts to other health plans and refined operational processes, laying groundwork for growth in amid increasing demand for cost-containment in employer-sponsored . The period marked a focus on proving the viability of third-party mail-order models, with revenues beginning from low millions as membership grew modestly from Sanus's network.

Expansion Through Acquisitions (1989–2011)

Following its acquisition by in 1989, which provided financial backing for growth, Express Scripts went public in , raising capital to pursue expansion in the (PBM) sector. This period marked a shift toward aggressive acquisition strategy, starting with smaller entries into new markets and accelerating with larger deals that consolidated and enhanced service capabilities. By the early , the company had secured major clients such as FHP International Corp. and Lockheed Corp., but was supplemented by targeted buys to build infrastructure for mail-order , services, and international operations. In 1995, Express Scripts acquired Eclipse Claims Services, a Canadian PBM, enabling entry into the international market and adding clients including and Prudential divisions. The pace intensified in 1998 with the $445 million purchase of ValueRx, the PBM unit of Columbia/HCA Corp., which positioned Express Scripts as the largest independent U.S.-based PBM at the time by expanding its network claims processing and formulary management scale. This was followed in April 1999 by the $700 million acquisition of Diversified Pharmaceutical Services from SmithKline Beecham Corp., further solidifying its ranking as the third-largest U.S. PBM and boosting annual drug spend management to nearly $10 billion through integrated data analytics and rebate negotiation enhancements. The 2000s saw continued consolidation amid rising healthcare costs and PBM demand. In February 2002, Express Scripts agreed to acquire National Prescription Administrators, the largest private PBM, for $515 million in stock, adding over 4 million covered lives and strengthening third-party administration capabilities. In December 2003, it purchased CuraScript Pharmacy for $335 million in cash, entering the specialty pharmacy segment for high-cost drugs like and hemophilia treatments, which diversified revenue beyond traditional generics and retail networks. The 2005 $1.3 billion acquisition of Priority Healthcare expanded distribution for specialty and home infusion services, while the 2007 purchase of ConnectYourCare introduced consumer-directed health plans with personalized benefit designs. By 2009, the $4.675 billion deal for WellPoint's NextRx subsidiaries closed, integrating mail-order and specialty operations to handle an additional $11 billion in annual prescriptions and enhancing in rebate capture. These acquisitions collectively drove revenue from under $1 billion in the mid-1990s to over $20 billion by 2010, primarily through synergies in claims processing efficiency, formulary control, and client retention rates exceeding 90 percent in core segments, though integration challenges occasionally arose from disparate IT systems in acquired entities. The reflected causal dynamics in the PBM industry, where scale enabled better pharmaceutical manufacturer negotiations for rebates—often 20-30 percent of list prices—while empirical data from post-merger outcomes showed sustained cost savings for clients via generic substitution rates above 70 percent. No major antitrust blocks occurred during this era, as reviews focused on potential rebate pass-through rather than outright market foreclosure.

Merger with Medco Health Solutions (2012)

In July 2011, Express Scripts announced a definitive merger agreement to acquire in a -and- transaction valued at approximately $29.1 billion, including the assumption of debt. The deal proposed combining the two largest benefit managers (PBMs) in the United States, creating a new entity under that would manage benefits for over 100 million covered lives and generate projected annual revenues exceeding $90 billion. Medco shareholders were to receive $28.81 per share in or Express Scripts , representing a 19% premium over Medco's closing price prior to the announcement. The merger faced significant antitrust scrutiny from the (FTC), which issued a second in August 2011, extending the review process. Concerns were raised by independent pharmacists, consumer groups, and members of , including hearings by the Judiciary Subcommittee on Antitrust, Competition Policy, and Consumer Rights in September and December 2011, highlighting potential reductions in competition that could harm rural pharmacies and increase pricing power over drug manufacturers and retailers. Opponents argued the combined entity would control about 75-80% of the U.S. PBM market, potentially enabling practices like steering patients to affiliated mail-order and specialty pharmacies at the expense of local providers, though proponents countered that the merger would enhance bargaining leverage to lower drug costs amid rising healthcare expenses. Shareholders of both companies approved the transaction in December 2011, with Medco shareholders reaffirming support after an initial vote. On April 2, 2012, the FTC approved the merger by a 3-1 vote after an eight-month investigation, determining it would not substantially lessen competition, as the PBM industry remained dynamic with opportunities for new entrants and the deal promised $1 billion in annual cost savings passed to clients through rebates and formulary efficiencies. The merger closed the same day, with George Paz serving as CEO of the combined company headquartered in , . Post-merger integration focused on unifying operations to improve clinical outcomes and affordability, including expanded use of evidence-based formularies and services, though subsequent analyses noted concentrated that influenced rebate negotiations with pharmaceutical firms. The transaction marked a pivotal consolidation in the PBM sector, reducing the number of major players and prompting ongoing debates about regulatory oversight of in healthcare supply chains.

Acquisition by Cigna and Integration (2018)

On March 8, 2018, Cigna Corporation announced its agreement to acquire Express Scripts Holding Company in a cash-and-stock transaction valued at approximately $67 billion, including the assumption of $15 billion in debt. The deal offered Express Scripts shareholders $48.75 in cash plus 0.2434 shares of Cigna common stock per share, representing a 31% premium over Express Scripts' closing price of $73.42 on March 7, 2018. Post-merger ownership was structured such that Cigna shareholders would hold about 64% of the combined entity, with Express Scripts shareholders retaining 36%; the combined company retained the Cigna name and headquarters in , while Express Scripts maintained its operations and base in , . The acquisition received shareholder approvals from both companies in August 2018 and cleared U.S. Department of Justice antitrust review as a vertical merger without requiring divestitures. The transaction closed on December 20, 2018, earlier than the anticipated year-end deadline, enabling immediate operational alignment. David M. Cordani continued as president and CEO of the enlarged Cigna, overseeing the integration of Express Scripts' capabilities with Cigna's and services portfolio to pursue cost reductions through enhanced data analytics, value-based care models, and efficiencies. Initial integration efforts focused on segment reorganization, with Express Scripts' operations reclassified under a new Health Services segment effective in the fourth quarter of , incorporating pharmacy revenues from the post-closing period. The combined entity projected synergies including double-digit accretion and targeted adjusted income from operations of $20–$21 per share by 2021, driven by improved affordability and predictability in drug pricing and benefit management. Concurrently, Cigna announced a $200 million community investment commitment and launched the Healthier Kids for Our Future initiative, a $25 million, five-year program starting in 2019 to combat childhood hunger, signaling early post-acquisition priorities in .

Operations Under The Cigna Group (2019–Present)

Following the acquisition's completion on December 20, 2018, Express Scripts integrated its operations into Cigna Corporation starting in , combining mail-order and specialty pharmacy functions to streamline services and capture synergies in (PBM). This merger amplified Cigna's health services revenue, with third-quarter sales reaching $24.88 billion, driven by Express Scripts' contributions to rebate negotiations, formulary design, and for over 100 million covered lives. Integration efforts emphasized cost containment, including expanded options integrated into Cigna's broader network, which supported clinical adherence and reduced out-of-pocket expenses for members. In September 2020, Cigna rebranded its health services division—including Express Scripts—as Evernorth Health Services, positioning Express Scripts as the core PBM engine within a platform that also encompasses specialty (via ), care delivery, and tools. Under this structure, Express Scripts managed benefits by prioritizing generics, negotiating manufacturer rebates, and enforcing formulary exclusions to lower net costs, with operations supported by 24/7 member access via app and phone. In February 2023, Cigna reorganized as The Cigna Group, with Evernorth operating as a distinct division focused on unregulated services like PBM, generating revenue growth through scaled operations while maintaining Express Scripts' headquarters in . A pivotal early came in December 2019, when Express Scripts collaborated with Prime Therapeutics on a three-year agreement, under which Express Scripts handled retail network management, manufacturer contracting, and rebate aggregation for Prime's clients, effectively expanding its influence to an additional 27 million lives without full ownership overlap. This arrangement enhanced for drug pricing but drew later antitrust scrutiny in states like , where it was alleged to suppress independent reimbursements. Subsequent initiatives included the 2023 Rural Health Access program, which boosted reimbursements and added services like vaccinations at independent pharmacies to improve access in underserved areas, and a 2024 tie-up with CPESN to integrate pharmacists into value-based care models. From 2020 to 2025, Express Scripts emphasized digital and transparency tools, such as the Real-Time Prescription Benefit tool for point-of-sale savings and annual formulary updates like the 2025 National Preferred Formulary, which excluded higher-cost drugs in favor of clinically equivalent, lower-priced alternatives to drive savings. In response to regulatory pressures on PBM practices, Evernorth introduced ClearNetwork in 2025, a simplified pricing model passing 100% of rebates and fees directly to clients without spreads, aiming to enhance predictability amid biosimilar expansions projected to impact $100 billion in specialty spend over five years. These efforts sustained operational focus on affordability, with Express Scripts handling home delivery for maintenance medications and specialty infusions while adapting to federal reforms on drug pricing transparency.

Business Model and Services

Core Pharmacy Benefit Management Functions

Express Scripts performs core functions, including real-time , pharmacy network administration, and clinical , to administer benefits for plans, employers, and programs. These operations enable electronic processing of claims at the point of dispensing, verifying eligibility, coverage, formulary status (as determined separately), requirements, and prior authorizations before approving or denying to pharmacies. In handling claims for over 110 million members—representing about one in three —Express Scripts achieves high efficiency, processing 99.1% of specialty drug claims for commercial and health plan payers. Pharmacy network management constitutes a foundational service, involving the and maintenance of contracts with retail, independent, and pharmacies to ensure broad geographic access and competitive dispensing fees. Express Scripts administers networks serving approximately 60 health plans, 2,300 employers, and 42 entities, facilitating member choice while enforcing standards for , compliance, and rates. This includes performance-based contracting to incentivize adherence to clinical guidelines and cost controls, supported by a of 18,000 employees nationwide. Clinical tools, such as requirements, step therapy protocols, and quantity limits, are applied to promote evidence-based prescribing and prevent overuse or misuse of medications. Express Scripts employs over 1,000 specialized pharmacists, physicians, and nurses, along with 3,500 patient service advocates, to review complex cases and ensure therapeutic appropriateness, particularly for high-cost or high-risk drugs. Their advanced initiatives have generated annual savings of $4.6 billion for clients by averting unnecessary expenditures, equivalent to 10-13% of pharmacy spend, through interventions like preferred alternative recommendations. Record-keeping and reporting form an essential backend function, aggregating claims data for analytics, compliance auditing, and to inform plan sponsors on utilization patterns and outcomes. These systems support regulatory reporting and enable interventions to optimize drug adherence and .

Negotiation, Rebates, and Formulary Management

Express Scripts negotiates with pharmaceutical manufacturers to secure rebates and discounts on , primarily in exchange for preferred placement on its formularies or higher utilization volumes. These negotiations leverage the company's , representing approximately 25% of the U.S. market, to extract concessions that reduce net drug costs for clients. Rebates are calculated based on actual drug utilization by plan members and are paid quarterly by manufacturers to Express Scripts, which then distributes the majority to health plan sponsors. In its rebate model, Express Scripts passes through over 95% of collected rebates to clients, retaining the remainder as compensation for negotiation and administrative services, a practice it has maintained since at least 2022. Clients can select from various economic arrangements, including full rebate pass-through options with transparent pricing, where plan sponsors pay exactly what Express Scripts reimburses pharmacies plus a . However, federal investigations, including a 2024 FTC lawsuit, allege that this rebate system incentivizes PBMs to favor high-rebate drugs over lower-cost alternatives, artificially inflating list prices—particularly for insulins—and distorting by prioritizing manufacturer payments over affordability. Express Scripts has contested these claims, arguing that rebates promote and lower net costs, while offering 100% auditable models to address transparency concerns. Formulary management at Express Scripts involves developing tiered lists of covered drugs, where decisions prioritize clinical appropriateness, safety, and efficacy over cost, according to the company's stated principles. The process includes pharmacist and physician reviews of clinical data, with exclusions applied to drugs deemed less effective or redundant; for instance, the 2025 formulary excluded high-cost biologics like Humira biosimilars in favor of lower-list-price alternatives from select manufacturers. Preferred tiers typically require higher manufacturer rebates, linking formulary position to negotiation outcomes, though Express Scripts maintains that rebate guarantees do not override evidence-based assessments. Critics, including state attorneys general in a 2025 lawsuit, contend this creates conflicts where formulary exclusions coerce larger rebates, potentially limiting access to clinically equivalent options and contributing to higher out-of-pocket costs for patients.

Specialty Pharmacy and Mail-Order Services

Express Scripts delivers specialty pharmacy services primarily through , its dedicated specialty pharmacy under the Evernorth umbrella, focusing on high-cost, complex medications for chronic and rare conditions including cancer, hepatitis C, , multiple sclerosis, rheumatoid arthritis, and bleeding disorders. provides integrated support such as personalized patient counseling by therapy-specific pharmacists, adherence monitoring via refill reminders and scheduled deliveries, financial assistance navigation, and 24/7 access to clinical experts, all coordinated with prescribers to optimize therapy outcomes. These services operate as a home delivery model, ensuring medications are dispensed with cold-chain logistics where required and without additional fees beyond standard cost-sharing for eligible members. Specialty drugs represent a significant portion of expenditures; for instance, prescriptions for such medications, used by under 2% of patients, comprised 51% of overall costs as of 2022, driven by launches of biologics and therapies with list prices often exceeding $100,000 annually per patient. Express Scripts manages these through formulary placement, protocols, and rebate negotiations with manufacturers, aiming to balance access with cost containment, though utilization growth in categories like and has contributed to year-over-year spending increases of 10-15% in commercial plans. Complementing specialty offerings, Express Scripts' mail-order service, branded as Express Scripts Pharmacy, enables of and chronic medications, typically in 90-day supplies to enhance and adherence while reducing retail copays by up to 30% compared to 30-day fills at network pharmacies. For certain plans, filling long-term or maintenance medications requires use of Express Scripts Pharmacy, notified by the message "your prescription plan requires home delivery to fill your long-term medication"; this promotes cost savings and adherence, though requirements vary by plan, with some allowing initial retail fills before mandating home delivery. Members can initiate orders , via mobile app, phone, or e-prescription, with free standard shipping (10-14 days) or expedited options, automatic refill scheduling, and real-time tracking; this service processed millions of prescriptions annually, particularly for cardiovascular, , and respiratory therapies, yielding estimated savings of $1-2 per day per member through bulk dispensing efficiencies. For specialty items, mail-order integrates seamlessly with Accredo's model, supporting limited-distribution drugs that require manufacturer-restricted handling.

Digital and Analytics Tools

Express Scripts offers members a suite of digital tools accessible via its online portal and mobile application, enabling prescription refills, order tracking, payment management, and automated reminders for medication adherence. These platforms support integration, reducing visits and providing real-time updates on shipments and claims status. In December 2019, Express Scripts introduced the Formulary, a curated selection of and remote monitoring services designed to assist payers in covering evidence-based tools for management and wellness. Launching in January 2020 with an initial roster of 15 solutions, including mobile apps for personalized health tracking and clinically validated programs, the formulary emphasizes safety, usability, and relevance, vetted for effectiveness and . This initiative facilitates on-the-go health management, such as symptom monitoring and behavioral interventions, integrated with benefits to enhance patient outcomes without requiring additional infrastructure from employers. On the analytics front, Express Scripts deploys proprietary platforms like , a PHI-compliant system built with R, Shiny applications, and to analyze drug trend , customer feedback via , and predictive forecasting, contributing to a 10-point improvement in Net Promoter Scores and cost reductions through targeted interventions. Complementing this, partnerships with SAS enable predictive modeling for medication adherence, scoring patients based on integrated prescription, medical, and lab via tools like ScreenRx to proactively address non-adherence risks. Through Evernorth's Intelligence+ suite, Express Scripts applies advanced and to , uncovering utilization patterns, predicting clinical gaps, and generating financial risk assessments for clients. Specialized tools include myDataSense, launched by subsidiary in November 2018, which aggregates pharmacy events, prescriber data, and drug references into visual dashboards for analytics, aiding in utilization review and cost control. These capabilities support broader initiatives like the Evernorth Research Institute's data-driven studies on and affordability, leveraging Express Scripts' claims data for evidence-based formulary decisions.

Corporate Structure

Headquarters and Organizational Integration

Express Scripts maintains its corporate headquarters at 1 Express Way, , Missouri 63121, located in unincorporated North St. Louis County. This 315,000-square-foot facility serves as the primary operational hub for the company's activities, including administrative functions and key decision-making. The campus has been central to Express Scripts since its consolidation in the region, supporting a focused on claims , formulary development, and client services. Following its acquisition by Cigna Corporation—completed on December 20, 2018, in a $67 billion transaction—Express Scripts retained its headquarters, distinct from Cigna's primary location at 900 Cottage Grove Road, . This geographic separation preserved operational continuity for Express Scripts' specialized PBM functions while enabling synergies with Cigna's broader portfolio. The deal emphasized , allowing coordinated management of medical and pharmacy benefits without immediate relocation of core operations. Organizationally, Express Scripts operates as a key component of Evernorth Health Services, a division of The Cigna Group (formerly Cigna Corporation, rebranded in ). Evernorth encompasses Express Scripts' PBM services alongside specialty pharmacy (e.g., ), care management (e.g., eviCore), and behavioral solutions, facilitating data-driven integration across the health services ecosystem. This structure supports The Cigna Group's model of combining (via Cigna Healthcare) with ancillary services, aiming to align incentives for cost containment and patient outcomes through shared analytics and rebate negotiations. Express Scripts reports into Evernorth leadership, with its executive team contributing to group-wide strategy while maintaining autonomy in day-to-day PBM execution.

Leadership and Key Executives

Adam Kautzner, PharmD, has served as President of Express Scripts since January 18, 2023, leading operations, formulary strategies, and integration with Evernorth Health Services under The Cigna Group. In this role, Kautzner oversees , specialty services, and efforts to manage drug costs amid regulatory scrutiny on PBM practices; prior to his appointment, he held senior positions including Senior of at Express Scripts, where he focused on pharmaceutical contracting and vendor negotiations. On October 8, 2025, Kautzner was appointed chair of the board for the Pharmaceutical Care Management Association (PCMA), the leading PBM group, highlighting his influence in advocating for industry positions on rebate retention and transparency reforms. Prior leadership includes , who was CEO of Express Scripts from September 2016 until his retirement at the end of 2021, during which he managed the post-acquisition transition into Cigna's structure and expanded digital tools for claims processing. Wentworth's tenure emphasized cost containment through rebate negotiations, reporting $100 billion in annual savings for clients by 2020. Following the 2018 Cigna acquisition, Express Scripts executives like Eric Palmer (Evernorth CEO from 2022) and Steven Miller (former chief clinical officer) contributed to integrated care models, though Palmer departed the company in March 2025 amid broader Cigna management reshuffles driven by rising healthcare costs. Key supporting executives include Katie Walsh, Senior and , responsible for operational efficiency and mail-order fulfillment scaling to over 100 million annual prescriptions. Christine Gilroy, MD, MSPH, FACP, appointed in November 2021, directs clinical guidelines and evidence-based formulary decisions to address rising specialty drug expenditures. Nikki White serves as and General Manager of the Health Plan Division, focusing on employer-sponsored benefit customizations. These roles report ultimately to Cigna Group CEO , reflecting Express Scripts' subordination to corporate oversight since 2018, with decisions on rebates and pricing aligned to Evernorth's $140 billion in annual pharmacy spend management as of 2024.

Financial Performance

Pre-Merger Financial Milestones

Express Scripts, Inc. was incorporated in September 1986 as a provider of claims processing services and went public on the on , , at an initial share price of $13, with shares reaching a high of $35.25 early in amid rapid post-IPO growth driven by expanding mail-order and claims management operations. A transformative milestone came with the , 2012, completion of its $29.1 billion merger with , Inc., in a cash-and-stock transaction valued at $71.36 per Medco share; this deal, approved by the , combined the two largest pharmacy benefit managers, nearly doubling Express Scripts' scale, enhancing negotiating power with drug manufacturers, and propelling combined annual revenues toward $100 billion in subsequent years through synergies in formulary management and specialty drug handling. Revenue growth accelerated post-merger, with 2010 figures (pre-merger) at approximately $45 billion, up from $24.7 billion in 2009, reflecting gains from client contracts and operational efficiencies; by 2016, annual revenues had climbed to $100.752 billion, supported by increased claims volume exceeding 1 billion annually and expansion in specialty services. The company demonstrated sustained profitability, with adjusted earnings per diluted share rising 28% year-over-year to $2.43 in the third quarter of 2017, underscoring cost containment strategies and rebate optimization amid rising drug prices; full-year 2017 net revenues approximated $100 billion, positioning Express Scripts as a dominant player ahead of its 2018 acquisition by Cigna.

Post-Acquisition Economics Within Cigna

The acquisition of Express Scripts by Cigna, completed on December 20, 2018, for approximately $67 billion, integrated the benefit manager into Cigna's operations under the Evernorth Health Services segment, fundamentally reshaping the company's economic profile by adding high-volume revenues and scale advantages. This enabled Cigna to capture greater value from negotiations, rebates, and distribution, with Express Scripts contributing the bulk of post-acquisition -related . In , the first full year of integration, Cigna's total revenues surged to $153.6 billion from $49 billion in 2018, driven predominantly by Express Scripts' $100 billion-plus in prior-year services revenue now consolidated within Cigna. Adjusted revenues for reached $140.2 billion, reflecting initial synergies in administrative efficiencies and opportunities between and benefits. Express Scripts' economics bolstered Cigna's profitability through rebate retention and cost containment, with the company projecting over $600 million in annual retained synergies from reduced overhead and enhanced formulary leverage. By 2023, Evernorth Health Services, led by Express Scripts, generated $153.5 billion in —comprising about 78% of Cigna's total $195.3 billion—up 9% from the prior year, fueled by a 40% increase in retail network claims volume to over 1.3 billion prescriptions annually. This segment's growth outpaced Cigna's overall 8% rise, demonstrating Express Scripts' role in driving accretive via expanded mail-order fulfillment and specialty , which accounted for higher-margin services. Adjusted from operations for Cigna as a whole climbed to levels supporting $7.9 billion in 2024 guidance, with pharmacy benefits yielding over 95% rebate pass-through to clients under certain contracts, though net retention supported internal margins. Into 2024, revenues exceeded $185 billion, contributing to Cigna's total of $247.1 billion—a 27% year-over-year increase—while shareholders' reached $3.4 billion. Express Scripts' platform sustained this trajectory amid rising drug costs, with Express Scripts' claims processing efficiency enabling Cigna to weather GLP-1 demand spikes and regulatory scrutiny without proportional margin erosion in core PBM functions. However, Evernorth's operating profit margins trended downward from 4.62% in 2020 to lower levels by 2024, attributable to investments in digital tools and competitive pricing pressures, though absolute adjusted rose to $26.32 for the year. Overall, the acquisition delivered sustained economic value, positioning Express Scripts as a high-revenue engine that offset slower medical segment growth and enhanced Cigna's leverage in a concentrated PBM market.

Research and Publications

Drug Trend Reports

Express Scripts publishes annual Drug Trend Reports that quantify changes in spending across its client base, primarily commercial and Medicare plans, using data from adjudicated claims for tens of millions of covered members. The core metric, "drug trend," represents the year-over-year percentage change in per-member-per-year (PMPY) expenditures, adjusted for factors including utilization rates, unit costs, therapeutic mix shifts, new launches, and generic or competition, often incorporating net rebates negotiated by the PBM. These reports, derived from Express Scripts' proprietary , emphasize how formulary , step , and prior authorizations influence trends, typically reporting lower growth rates for clients employing their strategies compared to broader market estimates. Specialty medications have dominated findings since the mid-2010s, surpassing 50% of total spend in commercial plans by 2021 and projected to grow 10-15% annually through therapies for , , and rare diseases. For example, the 2016 report documented specialty trend growth at 13.3%, the lowest since tracking began, crediting PBM interventions amid rising prices for brands like those for . In 2019, overall trend stabilized at 2.3%, buoyed by generic entries offsetting specialty launches, though inflammatory condition drugs drove nearly half of spending increases. Biosimilars, such as alternatives entering in 2023, are forecasted to curb costs, while and cancer generics provide partial relief against incidence-driven utilization rises. Recent reports spotlight (GLP-1) agonists, such as , as primary escalators of traditional drug spend, with 2024 trend reaching 8.9% overall—comprising 6.1% from utilization and inflation—fueled by off-label demand. The companion 2025 Pharmacy in Focus analysis projects 73.1% GLP-1 utilization growth for by year-end, contributing 46.8% to spend acceleration, yet notes >50% discontinuation within 12 months among users, alongside surging youth uptake (84.6% increase from 2023-2024). Express Scripts advocates clinical safeguards like evidence-based criteria and lowest-net-cost formulary positioning to temper these dynamics, asserting such measures sustained net trends below gross estimates in prior years.

Health Decision Science Initiatives

Express Scripts' Health Decision Science integrates behavioral sciences, clinical specialization, and actionable data to inform better choices in pharmacy benefits management, focusing on drug selection, pharmacy networks, and overall health behaviors. This framework emerged prominently after the 2012 merger with , enabling targeted interventions to boost adherence, optimize costs, and enhance outcomes. One key initiative involved a collaboration with , applying Health Decision Science to deliver personalized and data-driven recommendations for patients with chronic conditions, aiming to reduce non-adherence rates that contribute to higher long-term expenses. The program emphasized behavioral nudges alongside clinical guidance to encourage consistent use. The science has also supported research on specialty medications, where analyses identified strategies like and manufacturer discounts to curb per-member cost growth from 17.0% in 2012 to projected lower trends through evidence-based protocols. Similarly, studies of enrollees used these principles to highlight adherence gaps and promote lower-cost alternatives without compromising efficacy. In broader applications, Health Decision Science guides formulary designs and routing to clinically superior, cost-effective options, as evidenced in company roadmaps emphasizing empirical data over traditional models to address rising expenditures. These efforts, while self-reported by Express Scripts, align with observable reductions in trend rates in their annual drug reports.

Economic and Healthcare Impact

Evidence of Cost Reductions and Efficiency Gains

Express Scripts implements cost reductions through manufacturer rebate negotiations, generic and substitution incentives, and tools like step therapy, which encourage the use of lower-cost, clinically effective alternatives before higher-priced options. These mechanisms have lowered net drug expenditures for payers by leveraging scale to secure discounts and promote cost-effective prescribing. In 2022, 73% of Express Scripts members incurred less than $100 in annual out-of-pocket costs for medicines, with an average of $14.49 for a 30-day supply, maintaining flat cost-sharing over five years despite drug price inflation exceeding 10 times that rate. The Patient Assurance Program generated $18 million in insulin savings for members that year, accumulating over $45 million since , while boosting adherence by 30% and halving diabetes-related cost shares. Value-based pricing initiatives further demonstrate efficiency, such as point-of-sale rebates yielding $319 average savings per Praluent prescription, alongside improved adherence. Commercial client drug spending rose only 1.5% in 2017, a slowdown attributed to rebate capture and generic utilization amid list price hikes. Home delivery pharmacy services enhance operational efficiency by streamlining fulfillment and reducing waste, contributing to lower administrative burdens and higher adherence rates that indirectly curb long-term healthcare costs. PBM rebate negotiations, including those by Express Scripts, reduce payers' net acquisition costs, though empirical pass-through to end-users depends on plan design.

Criticisms of Pricing Practices and Market Concentration

Express Scripts, as one of the largest pharmacy benefit managers (PBMs), has faced scrutiny for contributing to high levels of in the U.S. PBM industry, where the three dominant players—CVS Caremark, OptumRx, and Express Scripts—collectively process approximately 80% of prescriptions. Nationally, Express Scripts holds about 17-23% , ranking second behind . In specific markets like Michigan's and commercial sectors, its dominance reaches 89%, enabling practices such as steering patients to affiliated mail-order pharmacies and suppressing independent reimbursements. This concentration, critics contend, reduces competition, limits consumer choice, and allows PBMs to extract higher fees from payers while underpaying pharmacies, potentially leading to pharmacy closures and reduced service access. Pricing practices have drawn particular criticism for opacity and incentives that favor higher drug list prices over net cost reductions. The sued Express Scripts and other major PBMs in September 2024, alleging a rebate system that prioritizes drugs with inflated list prices to secure larger manufacturer rebates, artificially inflating insulin costs by up to 1,000% since 1996 despite minimal underlying increases. This structure, per the FTC, discourages formulary placement of lower-list-price alternatives, passing higher out-of-pocket costs to patients while PBMs retain undisclosed portions of rebates as profit. Independent analyses and lawsuits echo these concerns, claiming PBMs like Express Scripts engage in "spread pricing"—charging payers more than they reimburse pharmacies—and withhold rebate pass-throughs, contributing to overall drug spending growth exceeding 10% annually in some years. Legal actions underscore these issues. In April 2025, filed an antitrust against Express Scripts, accusing it of colluding with competitors to fix reimbursement rates at suppressed levels (e.g., at least 20% below competitive benchmarks) and leveraging to favor affiliates, resulting in higher costs for state health plans. A January 2024 class-action suit alleged Express Scripts conspired with other PBMs to artificially depress reimbursements, harming pharmacies and consumers. Similarly, Vermont's sued Express Scripts' parent Evernorth in July 2024 for practices driving up prescription costs through non-transparent rebate retention and network restrictions. Express Scripts has countered such claims, suing the FTC in September 2024 to retract a report it deems misleading and asserting that PBM negotiations yield net savings for payers, though on full rebate pass-through remains contested due to proprietary data. Pharmacists and patient advocates report tangible harms, including reduced medication access from restrictive networks and prior authorizations that delay care, exacerbating out-of-pocket burdens amid hikes. While PBMs defend their role in negotiating $200 billion+ in annual rebates, critics argue the concentrated model's lack of transparency obscures whether these translate to consumer benefits or merely redistribute costs, with independent pharmacies citing shortfalls as a key driver of 10-15% annual closures since 2010. These practices, if sustained, risk entrenching inefficiencies where high concentration enables over genuine cost control.

Empirical Data on Net Effects for Consumers and Payers

Empirical analyses indicate that pharmacy benefit managers (PBMs), including Express Scripts, have generated substantial net savings for payers such as insurers and employers through rebate negotiations and , though these benefits are often retained primarily by payers rather than passed directly to consumers. A study examining PBM interventions found they reduced overall spending by approximately 28% relative to a without such , primarily by lowering prices and influencing utilization without significantly restricting patient access to medications. For Express Scripts specifically, independent analysis of its formulary strategies estimated cumulative savings of about $26 billion for clients over six years ending in 2023, driven by preferential placement of lower-cost alternatives and rebate capture from manufacturers. Commercial plan sponsors using Express Scripts reported weighted average drug spending growth of just 2.3% in , attributed to increased volume of prescriptions rather than inflation, reflecting effective cost containment amid rising utilization. For consumers, net effects are more variable, with evidence of declining out-of-pocket (OOP) costs for generics but persistent challenges for branded and specialty drugs due to coinsurance tied to list prices rather than net costs after rebates. Insured consumers' direct OOP payments for generic drugs fell by about 50% between 2007 and 2016, coinciding with total generic prices dropping 80%, largely from PBM-driven generic substitution and tiered copays. However, practices like copay clawbacks—where PBMs or pharmacies recoup portions of copays—resulted in consumers overpaying relative to actual drug costs in 28% of generic transactions during this period, averaging $7.32 per instance. Express Scripts data from 2022 showed 73% of members spending less than $100 OOP annually on medicines, rising to 81% under $250 in 2023, though these figures reflect self-reported aggregates and may not account for forgone care due to cost barriers. In rebate distribution, such as in Texas health plans in 2023, PBMs passed $2.07 billion to issuers but only $15 million directly to enrollees out of $2.2 billion total rebates, limiting consumer-level relief. Countervailing evidence highlights practices that erode net benefits, particularly through spread pricing where PBMs charge payers more than they reimburse pharmacies, capturing margins that offset claimed savings. Express Scripts retained $23.3 million in such spreads from , between 2016 and 2019, per a U.S. Department of Health and Human Services , contributing to higher program costs without proportional payer reductions. Similarly, it overcharged a federal employee health plan by $45 million from 2016 to 2021 by withholding rebates and imposing undisclosed fees, illustrating how opaque contracting can diminish net payer savings. Overall, while payers experience verifiable reductions in net drug expenditures—estimated at up to 40% lower total spending even after PBM fees—consumers often bear disproportionate OOP burdens from list-price basing and limited rebate passthrough, with empirical gaps in access data complicating full causal attribution.

Fraud and Overcharging Allegations

In September 2024, the U.S. Federal Trade Commission filed an administrative complaint against Express Scripts, along with CVS Caremark and OptumRx, alleging that these pharmacy benefit managers (PBMs) artificially inflated insulin prices through practices such as spread pricing—where PBMs charge health plans more than they reimburse pharmacies—and retaining rebates via clawbacks rather than passing savings to patients. The complaint claims these entities, controlling about 80% of U.S. prescriptions, used exclusionary formularies to favor high-list-price insulins with larger manufacturer rebates, contributing to list price surges like Humalog's increase from $21 per vial in 1999 to $274 in 2017 (over 1,200%) and Novolog U-100's doubling from $122.59 in 2012 to $289.36 in 2018. By 2019, one in four insulin patients reportedly could not afford their medication due to these dynamics, with patients in deductible phases bearing full unreduced list prices. In April 2025, Michigan Attorney General sued Express Scripts and Prime Therapeutics for , alleging a 2019 agreement suppressed rates to independent pharmacies, enabling excessive PBM profits and contributing to pharmacy closures that created "pharmacy deserts" in 50% of neighborhoods and rural . The suit claims these actions violated the and laws by restricting access and raising costs for consumers and pharmacies, seeking termination of the agreement. Similarly, a January 2024 federal antitrust in the Western District of Washington accused Express Scripts of colluding with rivals Prime, Benecard, and Magellan to fix rates and fees, leveraging to impose unfavorable terms on pharmacies and seeking recovery of hundreds of millions in alleged overcharges. Vermont Attorney General Charity Clark's July 2024 lawsuit against Evernorth (Express Scripts' parent entity) and CVS alleged illegal in Vermont's commercial prescription market, where the firms control about 95% share, by prioritizing high-cost drugs on formularies to capture manufacturer rebates and fees while excluding lower-cost alternatives, thereby driving up overall drug costs and limiting patient access. The further claims Express Scripts steered patients to its affiliated pharmacies, harming local providers and lacking transparency in decisions that favor PBM profits over outcomes, with remedies including greater transparency and for unfair practices. Class action lawsuits have targeted excessive fees charged by Express Scripts and its specialty pharmacy to employer health plans, alleging fiduciary breaches by plan sponsors like and for permitting markups of 5,000% to 10,000% on drugs relative to acquisition costs. For instance, (a generic drug) was reportedly charged over $10,000 for a 90-day supply versus $28 available online, contributing to higher plan and beneficiary costs without commensurate value. In October , AG Nessel additionally sued Express Scripts and OptumRx for their role in the crisis, alleging with manufacturers for formulary placement kickbacks, failure to enforce dispensing standards, and promotion of use that breached contracts and created a under state , facilitating over-dispensing in a market where these PBMs hold over 80% share. These cases remain ongoing, with Express Scripts contesting many claims, including a September lawsuit against the FTC demanding retraction of a related PBM report deemed false and harmful.

Data Privacy and Information Breaches

In October 2008, Express Scripts received an extortion letter containing personal information on 75 individuals, including names, dates of birth, social security numbers, and limited prescription details, with threats to release data on millions of patients unless an unspecified ransom was paid. The company notified the FBI, conducted an internal investigation with forensics experts, and alerted the affected individuals; subsequent review led to notifications for approximately 700,000 customers whose personal and medical information may have been compromised, though the exact breach vector remained undetermined. A on Medical Review Institute of America, a to Express Scripts, compromised of unspecified numbers of current and former plan participants in late 2021, prompting Express Scripts to notify plan sponsors on December 15, 2021. The vendor agreed to handle individual notifications and offer credit monitoring, while plan sponsors assessed compliance with HIPAA breach notification requirements and potential indemnification under business associate agreements. Between April 30 and May 3, 2022, unauthorized actors accessed certain Express Scripts mobile application accounts via attacks using valid usernames and passwords, exposing names, details, prescription numbers, dosages, prescribing physicians' names, and names for 19,796 individuals as reported to the U.S. Department of Health and Human Services . Express Scripts detected the activity on May 1, locked affected accounts, reset passwords, and advised users to update credentials on linked accounts to mitigate risks. Express Scripts maintains HIPAA-compliant privacy practices, including business associate agreements with vendors and notifications of uses or disclosures of protected health information, but has faced allegations of misuse. In 2018, a class-action lawsuit claimed the company violated HIPAA by charging excessive fees for patient records beyond reasonable cost-based limits, though the case's outcome emphasized strict HIPAA fee constraints without confirming broader violations. A 2019 suit by independent pharmacies alleged improper sharing of submitted patient data in violation of HIPAA privacy rules, but the U.S. Court of Appeals for the Eighth Circuit dismissed it in 2020, ruling that HIPAA does not grant pharmacies control over data uses after submission to pharmacy benefit managers. No enforcement actions or fines for systemic HIPAA violations by Express Scripts have been documented in federal records.

Antitrust and Contract Disputes

In April 2025, the filed an antitrust lawsuit against Express Scripts Inc. (ESI) and Prime Therapeutics in federal court, alleging that a December 2019 agreement between the two PBMs suppressed reimbursement rates for independent pharmacies to levels below dispensing costs, in violation of the , Michigan Antitrust Reform Act, and state laws. The suit claims ESI, controlling approximately 89% of the PBM market in , allowed Prime access to its buying power and network in exchange for administrative fees and adoption of ESI's lower rates, contributing to independent pharmacy closures and "pharmacy deserts" in areas like half of Detroit's neighborhoods. Remedies sought include termination of the agreement and injunctive relief to restore competition. In September 2024, the (FTC) sued ESI, along with and OptumRx—the "Big Three" PBMs handling about 80% of U.S. prescriptions—for artificially inflating insulin prices through a rebate system that favors high list-price drugs from manufacturers. The FTC alleges ESI and affiliates prioritized rebates tied to elevated list prices (e.g., Humalog rising over 1,200% from $21 in 1996 to $274 in 2017), excluding lower-list-price competitors and generating hundreds of millions in revenue without corresponding services, which shifted costs to patients and reduced access for vulnerable groups. The complaint invokes Section 5 of the FTC Act for unfair methods of . Additional antitrust challenges include a July 2024 federal lawsuit by AIDS Healthcare Foundation (AHF) against ESI and subsidiary Accredo Health Group in the U.S. District Court for the Eastern District of Missouri, asserting ESI's monopoly power in Louisiana—covering over 70% of health plan enrollees—imposes anticompetitive restraints on specialty pharmacies, costing AHF revenues and limiting access to HIV and hepatitis C treatments. In February 2025, pharmacies secured a preliminary federal court order in Washington state denying ESI's motion to dismiss or transfer a class action alleging conspiracy with smaller PBMs like Prime, Benecard, and Magellan to leverage ESI's market power for imposing low reimbursements and high fees, advancing claims of antitrust price-fixing. Contract disputes have centered on provider network terminations. In 2025, ESI terminated its agreement with Pennsylvania-based Martella's Pharmacies chain despite an ongoing class-action filed in , citing undisclosed disciplinary histories of pharmacists; Martella's attorneys described the move as an "egregious act" violating patient access commitments, prompting plans for a federal temporary . Separately, compounding pharmacy HM Compounding Services LLC sued ESI for wrongful termination of provider agreements, alleging breaches based on misrepresented recredentialing details. These cases highlight tensions over transparency and network exclusion practices amid broader PBM scrutiny.

Regulatory Scrutiny and Company Defenses

The (FTC) initiated significant regulatory action against Express Scripts and two other major pharmacy benefit managers (PBMs)— and OptumRx—on September 20, 2024, filing an administrative complaint alleging that their rebate practices artificially inflated insulin prices by prioritizing high-list-price insulins from manufacturers like , , and to maximize rebates, which in turn raised net costs for payers and limited patient access to lower-priced options. The complaint, supported by internal documents and data analysis, claimed these PBMs controlled over 75% of the U.S. insulin market and engaged in exclusionary tactics, such as delisting competitors, that stifled and alternative insulin development. State-level scrutiny intensified in 2025, exemplified by Dana Nessel's antitrust lawsuit filed on April 28, 2025, against Express Scripts and Prime Therapeutics, accusing them of a 2019 agreement whereby Prime adopted Express Scripts' reimbursement formulas, which allegedly suppressed independent reimbursements below costs, reduced , and drove closures across and nationally. Tennessee's Department of Commerce and Insurance concluded a 2023 audit of Express Scripts with a consent order on September 12, 2025, requiring enhanced transparency in pricing and reimbursements amid findings of non-compliance with state PBM laws. Additionally, the obtained a on April 11, 2025, to advance an investigation into Express Scripts Canada's sector practices for potential anti-competitive conduct. Express Scripts has mounted legal defenses, including a September 17, 2024, federal lawsuit against the FTC seeking to vacate and retract its June 2024 interim PBM report, which the company described as containing "false and misleading" assertions about rebate pass-through and cost impacts, arguing the report relied on selective and ignored of net savings delivered to clients. In its October 9, 2024, answer to the FTC's insulin complaint, Express Scripts asserted affirmative defenses, including lack of antitrust injury, failure to state a claim under Section 5 of the FTC Act, and preemption by Medicare laws, while contending that rebate negotiations demonstrably lower overall drug spend for health plans without consumer harm. Company executives, including those from parent Cigna, have publicly maintained that PBM operations, including Express Scripts', generate billions in annual savings through formulary management and rebates, positioning the firm to adapt to prospective reforms without operational disruption.

References

  1. https://www.express-scripts.com/frequently-asked-questions/what-pharmacy-benefit-manager-or-pbm
  2. https://www.evernorth.com/our-solutions/express-scripts-pbm
  3. https://www.forbes.com/companies/express-scripts/
  4. https://newsroom.thecignagroup.com/Cigna-Completes-Combination-with-Express-Scripts-Establishing-a-Blueprint-to-Transform-the-Health-Care-System
  5. https://www.fiercehealthcare.com/payer/cigna-closes-67b-express-scripts-acquisition
  6. https://www.evernorth.com/our-solutions/express-scripts-pbs-member-experience
  7. https://www.evernorth.com/express-scripts-facts
  8. https://fortune.com/company/express-scripts-holding/
  9. https://oversight.house.gov/wp-content/uploads/2024/07/PBM-Report-FINAL-with-Redactions.pdf
  10. https://www.canada.ca/en/competition-bureau/news/2025/03/competition-bureau-advances-an-investigation-into-express-scripts-canadas-business-practices-in-the-pharmacy-sector.html
  11. https://www.companieshistory.com/express-scripts/
  12. https://www.stltoday.com/news/express-scripts-history-health/article_62f7b2a3-999d-5b12-8f27-259ac0342ed2.html
  13. https://www.referenceforbusiness.com/history2/17/Express-Scripts-Inc.html
  14. https://www.express-scripts.com/pharmacy/blog/35-years-of-home-delivery
  15. https://www.zippia.com/express-scripts-careers-4152/history/
  16. https://www.encyclopedia.com/social-sciences-and-law/economics-business-and-labor/businesses-and-occupations/express-scripts-inc
  17. https://www.levinassociates.com/02mamhead02/
  18. https://www.wsj.com/articles/SB101303375258048120
  19. https://www.nytimes.com/2003/12/23/business/company-news-express-scripts-to-acquire-specialty-pharmacy.html
  20. https://www.bizjournals.com/stlouis/stories/2005/08/01/story2.html
  21. https://www.annualreports.com/HostedData/AnnualReportArchive/e/NASDAQ_ESRX_2006.pdf
  22. https://www.sec.gov/Archives/edgar/vprr/0505/05051811.pdf
  23. https://www.businessinsurance.com/express-scripts-set-to-grow-with-buy-of-smithkline-pbm/
  24. https://www.sec.gov/Archives/edgar/data/885721/000095012311066983/c65523exv99w1.htm
  25. https://www.ftc.gov/news-events/news/press-releases/2012/04/ftc-closes-eight-month-investigation-express-scripts-incs-proposed-acquisition-pharmacy-benefits
  26. https://www.congress.gov/112/chrg/CHRG-112hhrg68401/CHRG-112hhrg68401.pdf
  27. https://www.drugchannels.net/2012/04/esrx-mhs-analysis-of-ftc-decision.html
  28. https://www.prnewswire.com/news-releases/express-scripts-and-medco-health-solutions-complete-merger-will-address-national-mandate-for-more-affordable-higher-quality-healthcare-145742115.html
  29. https://www.nytimes.com/2012/04/03/business/ftc-approves-merger-of-express-scripts-and-medco.html
  30. https://www.bloomberg.com/news/articles/2012-04-02/express-scripts-medco-win-approval-for-29-billion-deal
  31. https://s202.q4cdn.com/757723766/files/doc_events/2018/03/cigna-corp-esrx-acquisition-release.pdf
  32. https://www.advisory.com/daily-briefing/2018/12/21/cigna
  33. https://www.prnewswire.com/news-releases/express-scripts-stockholders-approve-acquisition-by-cigna-300702094.html
  34. https://www.aha.org/news/headline/2018-09-17-doj-approves-cigna-express-scripts-merger
  35. https://s202.q4cdn.com/757723766/files/doc_financials/2018/q4/4Q18-10K.pdf
  36. https://www.reuters.com/article/business/cigna-raises-2019-forecast-as-express-scripts-buyout-pays-off-idUSKBN1XA19T/
  37. https://www.drugchannels.net/2021/05/how-cignas-growing-pharmacy-platform.html
  38. https://s202.q4cdn.com/757723766/files/doc_financials/2019/ar/cigna-2019-annual-report.pdf
  39. https://www.biopharmadive.com/news/cigna-rebrand-express-scripts-evernorth/585364/
  40. https://www.express-scripts.com/who-we-are
  41. https://www.prnewswire.com/news-releases/cigna-evolves-brands-to-reflect-growing-portfolio-301744529.html
  42. https://www.thecignagroup.com/our-capabilities/evernorth-health-services
  43. https://www.prnewswire.com/news-releases/express-scripts-and-prime-therapeutics-collaborate-to-deliver-more-affordable-care-to-more-than-100-million-americans-300978059.html
  44. https://www.fiercehealthcare.com/payers/express-scripts-controls-nearly-90-pbm-market-michigan-new-lawsuit-says
  45. https://www.stocktitan.net/news/CI/express-scripts-r-launches-new-initiative-to-expand-rural-health-9fn5exnxn69u.html
  46. https://www.nasdaq.com/articles/cignas-ci-express-scripts-collaborates-with-cpesn-usa
  47. https://newsroom.cigna.com/latest-press-releases?category=779&l=100
  48. https://www.express-scripts.com/pdf/formulary/NPF_Preferred_Formulary_Exclusions2025.pdf
  49. https://newsroom.thecignagroup.com/latest-press-releases?category=779
  50. https://www.fiercehealthcare.com/payers/cigna-execs-say-evernorth-poised-weather-eventual-pbm-reform
  51. https://www.healthcaredive.com/news/cigna-express-scripts-plan-reform-q4-2024/738731/
  52. https://www.ncbi.nlm.nih.gov/books/NBK559746/
  53. https://www.pssny.org/page/PBMBasics
  54. https://content.naic.org/insurance-topics/pharmacy-benefit-managers
  55. https://jamanetwork.com/journals/jama-health-forum/fullarticle/2811344
  56. https://www.commonwealthfund.org/publications/explainer/2025/mar/what-pharmacy-benefit-managers-do-how-they-contribute-drug-spending
  57. https://www.evernorth.com/articles/drug-rebates-explained
  58. https://www.evernorth.com/sites/default/files/2024-03/HowExpressScriptsSharesInTheValueWeCreate.pdf
  59. https://www.drugchannels.net/2023/08/surprising-data-on-employer-pbm-rebate.html
  60. https://www.ftc.gov/news-events/news/press-releases/2024/09/ftc-sues-prescription-drug-middlemen-artificially-inflating-insulin-drug-prices
  61. https://oversight.house.gov/wp-content/uploads/2024/07/Express-Scripts-PBM-Report-Documents.pdf
  62. https://www.drugchannels.net/2025/01/the-big-three-pbms-2025-formulary.html
  63. https://www.naag.org/wp-content/uploads/2025/05/Express-Scripts-Complaint.pdf
  64. https://www.accredo.com/
  65. https://www.express-scripts.com/frequently-asked-questions/specialty-pharmacy
  66. https://militaryrx.express-scripts.com/faq/specialty-pharmacy-services
  67. https://www.evernorth.com/articles/specialty-drug-trends-and-utilization
  68. https://www.drugchannels.net/2021/07/pbms-and-drug-spending-in-2020-data.html
  69. https://www.express-scripts.com/rx
  70. https://www.express-scripts.com/frequently-asked-questions/home-delivery
  71. https://www.wellcare.com/en/hawaii/providers/medicare/pharmacy/express-scripts-pharmacy
  72. https://www.express-scripts.com/
  73. https://www.fiercehealthcare.com/payer/express-scripts-selects-first-crop-tech-tools-to-include-new-digital-health-formulary
  74. https://clarivate.com/life-sciences-healthcare/blog/express-scripts-pioneer-launches-curated-list-digital-therapeutics/
  75. https://www.express-scripts.com/partner/healthsolutions
  76. https://www.welldoc.com/news/express-scripts-improves-patient-access-to-digital-health-solutions/
  77. https://posit.co/about/customer-stories/express-scripts/
  78. https://www.pharmaceuticalcommerce.com/view/express-scripts-tackles-medication-adherence-with-sas-analytics
  79. https://www.forbes.com/sites/peterhigh/2013/07/29/94-billion-express-scripts-leverages-technology-and-analytics-to-improve-patient-outcomes/
  80. https://www.evernorth.com/capabilities/intelligence-plus
  81. https://www.prnewswire.com/news-releases/express-scripts-mymatrixx-launches-mydatasense-analytics-tool-300744947.html
  82. https://www.express-scripts.com/contact-us
  83. https://www.bloomberg.com/profile/company/0275481D:US
  84. https://www.paric.com/project/express-scripts-headquarters/
  85. https://www.clay.com/dossier/express-scripts-headquarters-office-locations
  86. https://www.usatoday.com/story/money/2018/03/08/cigna-express-scripts-acquisition/406096002/
  87. https://www.thecignagroup.com/about-us/contact-us
  88. https://www.drugchannels.net/2018/05/cigna-express-scripts-vertical.html
  89. https://www.healthcaredive.com/news/cigna-rebrands-health-services-division-including-express-scripts-as-ever/585248/
  90. https://www.evernorth.com/
  91. https://www.mercer.com/en-us/insights/us-health-news/vertical-integration-continues-with-cigna-esi-announcement/
  92. https://newsroom.cigna.com/2023-01-18-Evernorth-Names-Adam-Kautzner-President%2C-Express-Scripts
  93. https://www.thecignagroup.com/our-leaders/leadership-team/adam-kautzner
  94. https://www.healthcaredive.com/news/pcma-board-chair-adam-kautzner-express-scripts/802313/
  95. https://craft.co/express-scripts/executives
  96. https://www.evernorth.com/leadership
  97. https://www.forbes.com/sites/brucejapsen/2025/03/13/cigna-shakes-up-management-ranks-amid-rising-costs/
  98. http://www.modernhealthcare.com/people/cigna-brian-evanko-eric-palmer/
  99. https://newsroom.cigna.com/evernorth-names-new-chief-medical-officer-express-scripts
  100. https://jobs.cigna.com/us/en/blogarticle/executive-spotlight-nikki-white
  101. https://www.thecignagroup.com/our-leaders/leadership-team/
  102. https://www.crunchbase.com/organization/express-scripts/company_financials
  103. https://www.prnewswire.com/news-releases/express-scripts-and-medco-health-solutions-sign-definitive-merger-agreement-medco-shareholders-to-receive-291-billion-125940848.html
  104. https://www.sec.gov/Archives/edgar/data/1532063/000153206314000006/esrx-12312013x10k.htm
  105. https://www.bizjournals.com/stlouis/news/2018/03/09/barrett-toan-medicare-glaser-and-the-origins-of.html
  106. https://www.prnewswire.com/news-releases/express-scripts-announces-2018-third-quarter-results-300741613.html
  107. https://s202.q4cdn.com/757723766/files/doc_financials/2019/q4/cigna-corp-fourth-quarter-2019-release.pdf
  108. https://newsroom.thecignagroup.com/cigna-delivers-strong-2018-results-as-it-completes-express-scripts-transaction-company-positioned-for-significant-growth
  109. https://s202.q4cdn.com/757723766/files/doc_presentations/2018/03/1/cigna-corp-esrx-acquisition-investor-presentation.pdf
  110. https://www.managedhealthcareexecutive.com/view/cigna-s-2023-revenue-grew-8-to-195-3-billion
  111. https://www.drugchannels.net/2025/03/the-top-pharmacy-benefit-managers-of.html
  112. https://www.statista.com/statistics/985078/types-of-revenues-of-cigna/
  113. https://newsroom.thecignagroup.com/2025-01-30-The-Cigna-Group-Reports-Fourth-Quarter-and-Full-Year-2024-Results%2C-Establishes-2025-Outlook-and-Increases-Dividend
  114. https://www.stock-analysis-on.net/NYSE/Company/Cigna-Group/Ratios/Reportable-Segments
  115. https://www.drugchannels.net/2020/06/pbms-and-drug-spending-in-2019-cvs.html
  116. https://www.evernorth.com/drug-trend-report/2021-and-onward
  117. http://vbidcenter.org/wp-content/uploads/2017/02/Express-Scripts-2016-Commercial-Drug-Trend-Report-3.pdf
  118. https://www.fiercehealthcare.com/payer/express-scripts-drug-classes-are-driving-spending-growth
  119. https://www.drugchannels.net/2025/04/drug-channels-news-roundup-april-2025.html
  120. https://www.evernorth.com/pharmacy-in-focus-2025
  121. https://www.sec.gov/Archives/edgar/data/1532063/000119312513063930/d450292d10k.htm
  122. https://www.walgreensbootsalliance.com/news-media/press-releases/2013/express-scripts-and-walgreens-offer-new-solution-to-improve-patient-health
  123. https://www.prnewswire.com/news-releases/express-scripts-study-reveals-keys-to-controlling-specialty-drug-costs-195839241.html
  124. https://www.prnewswire.com/news-releases/new-express-scripts-analysis-reveals-trends-among-health-exchange-members-278496251.html
  125. https://www.healthwellfoundation.org/realworldhealthcare/express-scripts-provides-roadmap-to-improve-health-care-reduce-costs-and-streamline-delivery-of-the-medicine-patients-need/
  126. https://www.express-scripts.ca/sites/default/files/2023-04/ESC%2520DTR%2520EN%2520April%25205%25202023%2520final.pdf
  127. https://www.cagw.org/new-study-shows-pbms-lower-drug-prices/
  128. https://www.evernorth.com/articles/prescription-savings-express-scripts-2022
  129. https://www.fiercehealthcare.com/payer/express-scripts-value-based-programs-increasing-adherence-lowering-drug-costs
  130. https://www.drugchannels.net/2018/02/new-express-scripts-data-drug-spending.html
  131. https://express-scripts.ca/express-scripts-canada-introduces-new-business-model
  132. https://www.ftc.gov/system/files/ftc_gov/pdf/pharmacy-benefit-managers-staff-report.pdf
  133. https://www.ama-assn.org/health-care-advocacy/access-care/pbm-market-competition-hard-come
  134. https://www.michigan.gov/ag/-/media/Project/Websites/AG/releases/2025/April/Express-Scripts-Complaint.pdf
  135. https://www.bipc.com/a-blueprint-for-action-michigans-lawsuit-against-express-scripts-and-prime-therapeutics-signals-a-turning-point-for-independent-pharmacies-plan-sponsor-patients-and-state-enforcement
  136. https://clarivate.com/life-sciences-healthcare/blog/beyond-transparent-pricing-decoding-the-strategies-of-major-pbms/
  137. https://ncpa.org/newsroom/news-releases/2024/01/10/ncpa-applauds-class-action-lawsuit-alleging-collusion-between
  138. https://ago.vermont.gov/blog/2024/07/17/attorney-general-clark-sues-pharmacy-benefit-managers-illegally-driving-prescription-drug-costs
  139. https://www.ajmc.com/view/express-scripts-sues-ftc-over-pbm-report
  140. https://www.stlpr.org/health-science-environment/2024-05-17/pharmacists-patients-say-express-scripts-business-practices-bad-for-consumers
  141. https://www.naag.org/multistate-case/michigan-v-express-scripts-inc-et-al/
  142. https://pubsonline.informs.org/doi/10.1287/mnsc.2021.03331
  143. https://www.evernorth.com/articles/independent-analysis-demonstrates-value-pharmacy-benefit-managers-us
  144. https://www.drugchannels.net/2020/02/latest-express-scripts-data-slow-drug.html
  145. https://schaeffer.usc.edu/research/u-s-consumers-overpay-for-generic-drugs/
  146. https://www.evernorth.com/articles/express-scripts-evernorth-members-paid-less-their-share-prescriptions-2023-despite-drug
  147. https://www.michigan.gov/ag/news/press-releases/2025/04/29/ag-nessel-files-lawsuit
  148. https://bergermontague.com/news/berger-montague-antitrust-lawsuit-pharmacy-benefit-manager-express-scripts/
  149. https://www.bhfs.com/insight/emerging-class-action-litigation-trend-over-excessive-pbm-fees/
  150. https://www.michigan.gov/ag/news/press-releases/2024/10/24/ag-nessel-sues-pharmacy-benefit-managers-for-role-in-opioid-crisis
  151. https://www.reuters.com/article/business/healthcare-pharmaceuticals/express-scripts-reports-extortion-over-data-breach-idUSN06469022/
  152. https://www.networkworld.com/article/793428/lan-wan-express-scripts-discloses-extortion-threat-possible-data-breach.html
  153. https://www.darkreading.com/cyberattacks-data-breaches/breach-at-pharmaceutical-benefits-company-may-have-affected-700-000
  154. https://www.osc.ny.gov/files/press/pdf/express-scripts-shareholder-proposal.pdf
  155. https://www.haynesboone.com/news/blogs/hipaa-breach-by-express-scripts-vendor-triggers-plan-sponsor-actions
  156. https://www.hipaajournal.com/5-hipaa-regulated-entities-announced-hacking-incidents-that-exposed-phi/
  157. https://www.express-scripts.com/frontend/consumer-legal-ui/legal?type=Practices
  158. https://www.fiercehealthcare.com/payer/express-scripts-class-action-lawsuit-medical-records-overcharging-hipaa
  159. https://www.hipaajournal.com/express-scripts-hipaa-based-lawsuit-dismissed-by-court-of-appeals/
  160. https://www.aidshealth.org/2024/07/ahf-files-antitrust-action-against-express-scripts-pbm/
  161. https://ncpa.org/newsroom/qam/2025/02/18/pharmacies-win-preliminary-order-against-express-scripts-federal-court
  162. https://wjactv.com/news/local/an-egregious-act-express-scripts-terminates-contract-with-martellas-despite-lawsuit-pharmacy-customers-cambria-county-pennsylvania-johnstown-pbm-dispute-court-attorneys
  163. https://www.huschblackwell.com/express-scripts-inc
  164. https://www.duanemorris.com/articles/pharmacy_fights_back_against_pbm_termination_notice_1117.html
  165. https://www.frierlevitt.com/articles/tennessee-steps-up-pbm-oversight-consent-orders-target-caremark-and-express-scripts/
  166. https://www.ftc.gov/system/files/ftc_gov/pdf/611920.2024.10.09_esi_respondents_answer_and_defenses_0.pdf
Add your contribution
Related Hubs
User Avatar
No comments yet.